Suppr超能文献

miR-16、miR-146a、miR-192和miR-221在肝细胞癌和肝硬化患者外泌体中的诊断及预后价值

Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients.

作者信息

Fründt Thorben, Krause Linda, Hussey Elaine, Steinbach Bettina, Köhler Daniel, von Felden Johann, Schulze Kornelius, Lohse Ansgar W, Wege Henning, Schwarzenbach Heidi

机构信息

Department of Medicine I, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Institute of Medical Biometry and Epidemiology, 20246 Hamburg, Germany.

出版信息

Cancers (Basel). 2021 May 19;13(10):2484. doi: 10.3390/cancers13102484.

Abstract

We aimed to identify a specific microRNA (miRNA) pattern to determine diagnostic and prognostic value in plasma exosomes of hepatocellular carcinoma (HCC) patients. A two-stage study was carried out: exosomal miRNAs were quantified in plasma of HCC patients and healthy individuals by PCR-based microarray cards containing 45 different miRNAs (training cohort). Then, four deregulated miRNAs (miR-16, miR-146a, miR-192, and miR-221) were quantified in the validation analysis using exosomes derived from 85 HCC patients, 50 liver cirrhosis patients, and 20 healthy individuals. Exosomal miR-146a ( = 0.0001), miR-192 ( = 0.002) and miR-221 ( = 0.032) were upregulated only in HCC patients. Repeated 10-fold cross validation showed that miR-146a differentiated HCC from liver cirrhosis patients with AUC of 0.80 ± 0.14 (sensitivity: 81 ± 13%, specificity: 58 ± 22%) in a logistic regression model. High miR-192 presence is associated with poor overall survival (OS) in all HCC patients ( = 0.027) and was predictor of OS in HCC patients in an uni- and multivariate Cox regression model. Moreover, decreased miR-16 levels correlated with OS in liver cirrhosis patients ( = 0.034). Our results emphasized that exosomes secreted into the plasma carry differentially expressed miRNAs of which in particular, miR-192, miR-146, and miR-16 are promising diagnostic and prognostic markers for both HCC and liver cirrhosis patients.

摘要

我们旨在识别一种特定的微小RNA(miRNA)模式,以确定其在肝细胞癌(HCC)患者血浆外泌体中的诊断和预后价值。我们进行了一项两阶段研究:通过基于PCR的包含45种不同miRNA的微阵列芯片对HCC患者和健康个体血浆中的外泌体miRNA进行定量(训练队列)。然后,在验证分析中,使用来自85例HCC患者、50例肝硬化患者和20例健康个体的外泌体对4种失调的miRNA(miR-16、miR-146a、miR-192和miR-221)进行定量。外泌体miR-146a(P = 0.0001)、miR-192(P = 0.002)和miR-221(P = 0.032)仅在HCC患者中上调。重复10倍交叉验证显示,在逻辑回归模型中,miR-146a区分HCC和肝硬化患者的曲线下面积(AUC)为0.80±0.14(敏感性:81±13%,特异性:58±22%)。高表达的miR-192与所有HCC患者的总生存期(OS)较差相关(P = 0.027),并且在单因素和多因素Cox回归模型中是HCC患者OS的预测指标。此外,miR-16水平降低与肝硬化患者的OS相关(P = 0.034)。我们的结果强调,分泌到血浆中的外泌体携带差异表达的miRNA,其中特别是miR-192、miR-146和miR-16有望成为HCC和肝硬化患者的诊断和预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebc/8161187/2e829dd6f724/cancers-13-02484-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验